S&P ASX All Technology

US Dollar vs AUD

Level up your trading with our powerful tools and real-time insights all in one place.

Get Started

NTLA Intellia Therapeutics Inc

26.26

0.25 (0.96%)

Pre Market

Last Updated: 21:05:01

Delayed by 15 minutes

Annual Report to Security Holders (ars)

This regulatory filing also includes additional resources:
d474761dars.pdf

Intellia Therapeutics (NASDAQ:NTLA)
Historical Stock Chart
From Jun 2024 to Jul 2024

Click Here for more Intellia Therapeutics Charts.

Intellia Therapeutics (NASDAQ:NTLA)
Historical Stock Chart
From Jul 2023 to Jul 2024

Click Here for more Intellia Therapeutics Charts.

Intellia Therapeutics, Inc. News

Kuehn Law Encourages Investors of Intellia Therapeutics, Inc. to Contact Law Firm
Wednesday 3 July 2024 (2 weeks ago) • PR Newswire (US)

Intellia Therapeutics Announces CFO Transition
Wednesday 26 June 2024 (3 weeks ago) • GlobeNewswire Inc.

Intellia Announces Positive Clinical Proof-of-Concept Data for Redosing a CRISPR-Based Therapy with its Proprietary LNP-Based Delivery Platform
Wednesday 26 June 2024 (3 weeks ago) • GlobeNewswire Inc.

Intellia Therapeutics to Present the First-Ever Clinical Data From Patients Redosed with an Investigational In Vivo CRISPR Gene Editing Therapy at the Peripheral Nerve Society Annual Meeting 2024
Monday 17 June 2024 (4 weeks ago) • GlobeNewswire Inc.

Form 8-K - Current report
Saturday 15 June 2024 (1 month ago) • Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities
Saturday 15 June 2024 (1 month ago) • Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities
Saturday 15 June 2024 (1 month ago) • Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities
Saturday 15 June 2024 (1 month ago) • Edgar (US Regulatory)

Intellia Therapeutics Names Brian Goff to its Board of Directors
Friday 14 June 2024 (1 month ago) • GlobeNewswire Inc.

Form 8-K - Current report
Friday 14 June 2024 (1 month ago) • Edgar (US Regulatory)

Intellia Therapeutics Announces Positive Long-Term Data from Ongoing Phase 1 Study of NTLA-2002, an Investigational In Vivo CRISPR Gene Editing Treatment for Hereditary Angioedema (HAE)
Sunday 2 June 2024 (1 month ago) • GlobeNewswire Inc.

Form 10-Q - Quarterly report [Sections 13 or 15(d)]
Friday 10 May 2024 (2 months ago) • Edgar (US Regulatory)

More Intellia Therapeutics, Inc. News Articles

NLBNPIT239R3 20351221 26...

Delayed Upgrade Clock

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions